Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$14.84M+1769.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua R. Disbrow
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 76
- Beta
- 0.27
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -4.68
Financials
Revenue
$14.84M+1769.3%Net Income
$-3.88MEBITDA
$-2.35MFree Cash Flow
$-275.0KEPS (diluted)
$-0.20Shares Outstanding (diluted)
19.33M+14314925.9%Operating Expenses
$12.61MCash & Debt
$25.49MRevenue by Segment (annual)
$15.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $57.57M | $-14.25M | $-1.16 |
| 2025 | $66.38M | $-13.56M | $-2.16 |
| 2024 | $65.18M | $-15.84M | $-2.86 |
| 2023 | $107.40M | $-17.05M | $-5.11 |
| 2022 | $96.67M | $-108.78M | $-74.01 |
| 2021 | $65.63M | $-58.29M | $-69.60 |
| 2020 | $27.63M | $-13.62M | $-60.20 |
| 2019 | $7.32M | $-47.17M | $-1210.28 |
| 2018 | $3.66M | $-10.19M | $-3061.23 |
| 2017 | $3.22M | $-22.51M | $-193194.38 |
| 2016 | $2.56M | $-28.18M | $-1294738.36 |
| 2015 | $261.8K | $-7.72M | $-551671.71 |
| 2014 | $58.9K | $-5.58M | $-619854.44 |
| 2013 | $1.8K | $-57.3K | $-7164.75 |
Valuation
AYTUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (8)
- Newsbenzinga.com·5d ago·Neutral
Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket Shares of Aytu Biopharma Inc (NASDAQ:AYTU) rose sharply in pre-market trading after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceuticals.
View source ↗ - Newszacks.com·6d ago·Neutral
Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue Estimates Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.08 per share a year ago.
View source ↗ - Newsbusinesswire.com·6d ago·Neutral
AYTU Stock Alert: Halper Sadeh LLC is Investigating Whether Aytu BioPharma, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Aytu BioPharma, Inc. (NASDAQ: AYTU) to Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share.Halper Sadeh encourages Aytu shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763…
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
…delivering medicines around patients' needs, today announced that it has entered into a definitive merger agreement to acquire Aytu BioPharma, Inc. (“Aytu”) (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases.
View source ↗ - Newsseekingalpha.com·61d ago·Positive
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·61d ago·Neutral
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.
View source ↗ - Newsaccessnewswire.com·61d ago·Positive
…bcast today, September 22, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 full year and fourth quarter.
View source ↗ - Newsaccessnewswire.com·67d ago·Neutral
…er Operational and Financial Results on September 22, 2026 DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has …
View source ↗
Earnings
Tue, Feb 2(in 2 months)
Consensus estimate $-0.15 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.20 vs $-0.26beat
- Tue, Sep 22$-0.05 vs $-0.29beat
- Wed, May 13$-0.53 vs $-0.31miss
- Tue, Feb 3$-1.05 vs $-0.26miss
- Thu, Nov 13$-0.08 vs $-0.06miss
- Tue, Sep 23$-2.92 vs $-0.02miss
Estimates and results for AYTU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AYTU officers and directors.
- Bought
- $325k
- Sold
- $1k
11 trades
1 trade
- Disbrow Jarrettbought
- Disbrow Joshua R.bought
- Nantahala Capital Management, Llcbought
- Disbrow Joshua R.bought
- Pyszczymuka Gregbought
- Disbrow Joshua R.bought
- Disbrow Joshua R.bought
- Pyszczymuka Gregbought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AYTU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
